Summary
Core view: Windlas Biotech grew Q1 FY27 revenue 18% year-on-year to a record ₹248 crore, led by 29% growth in its generic formulations CDMO segment and 79% export growth. Reported PAT was roughly flat due to a ₹7.2 crore non-cash ESOP charge; excluding this, adjusted PAT grew 37%, which is the more meaningful measure of underlying earnings momentum.
Windlas Biotech is a CDMO formulations manufacturer for domestic branded-generics customers, with a growing exports business, delivering its 14th consecutive quarter of record revenue.
Q1 FY27 Snapshot
Revenue₹248 Cr+18% YoY, 14th record quarter
Reported PAT₹17-18 CrRoughly flat YoY
Adjusted PAT (ex-ESOP)₹25 Cr+37% YoY
CDMO segment₹207 Cr+29% YoY
| Metric | Reported | Ex-ESOP (adjusted) |
|---|---|---|
| EBITDA | ₹27 Cr | ₹34 Cr (+26% YoY) |
| ESOP charge | ₹7.2 Cr (non-cash) | Excluded |
Business Quality And Mix
Strengths
- 14th consecutive quarter of record revenue.
- CDMO formulations segment grew 29% YoY.
- Exports grew 79% YoY, diversifying the customer base.
- Adjusted (ex-ESOP) PAT grew 37% YoY, showing real underlying momentum.
Constraints
- Reported PAT is distorted by a non-cash ESOP charge, complicating headline comparisons.
- CDMO model concentrates revenue with a relatively small number of branded-generics customers.
- Completed a promoter-excluded buyback, using cash that could otherwise fund growth.
- Formulations CDMO margins are sensitive to input costs and customer contract terms.
Growth Drivers And Capacity Economics
Export growth+79% YoYQ1 FY27
CDMO segment growth+29% YoY₹207 Cr
Buyback₹47 Cr completedPromoter-excluded
Growth continues to be led by the CDMO formulations business and a rapidly scaling export franchise, alongside steady domestic branded-generics demand.
Management Guardrails And Credibility
| Objective | Target | Assessment |
|---|---|---|
| Revenue growth | Sustain record quarterly revenue | The company has now delivered 14 consecutive quarters of record revenue, a strong execution track record. |
| ESOP charge normalization | Non-cash ESOP charges should reduce over time as grants vest | Reported PAT growth should converge toward adjusted PAT growth as the ESOP charge normalizes. |
| Export scale-up | Continue growing the export business | 79% YoY export growth this quarter is a strong signal, though the export base is still smaller than domestic CDMO. |
Financial Quality
Adjusted PAT growth+37% YoYEx-ESOP
EBITDA (ex-ESOP)₹34 Cr+26% YoY
Trailing P/E35-36xReasonable for the growth rate
Final FY26 dividend₹6.30/shareRecently paid
| Quality test | Reading | Interpretation |
|---|---|---|
| Earnings quality | Reported PAT flat, but ex-ESOP PAT +37% YoY | The ESOP charge is a real but non-cash and largely one-off-per-grant item; adjusted PAT is the more representative measure of operating performance. |
| Segment quality | CDMO +29%, exports +79% YoY | Growth is broad-based across formulations CDMO and exports, not a single-customer spike. |
| Capital allocation | Completed a ₹47 crore promoter-excluded buyback | Returns cash to non-promoter shareholders, though it could alternatively fund growth capex. |
Valuation
Key Risks
- ESOP charges continuing to distort reported earnings.
- CDMO customer concentration.
- Export growth moderating from the current 79% pace.
- Input-cost and contract-term pressure on formulations margins.
- General pharma pricing and regulatory risk.
Projection: Next 2-4 Quarters
Investor Watchlist
- Adjusted vs reported PAT gap trend.
- CDMO segment growth and customer concentration.
- Export revenue growth and diversification.
- Dividend and buyback policy.
- Record-quarter streak continuation.